Second that.

Yesterday the FDA announced it has approved a second option for first-line immune checkpoint inhibitor monotherapy for metastatic EGFR/ALK-wildtype non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50% (or, interestingly, with PD-1 stained tumor-infiltrating immune cells covering ≥ 10% of the tumor area). Much like the preceding approval for pembro for this indication, atezolizumab has gained approval following abstract reporting of the IMpower110 trial at ESMO demonstrating a significant overall survival benefit with its use as monotherapy (median OS 20 months) versus upfront platinum-based chemo (median OS 13 months). TBL: You now have two options for first-line ICI monotherapy for metastatic EGFR/ALK-wildtype NSCLC. | FDA 2020